Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Mrp2 is involved in the efflux and disposition of fosinopril.

Green BR, Bain LJ.

J Appl Toxicol. 2013 Jun;33(6):458-65. doi: 10.1002/jat.1767. Epub 2011 Nov 17.

PMID:
22095822
2.

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

Breedveld P, Zelcer N, Pluim D, Sönmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH.

Cancer Res. 2004 Aug 15;64(16):5804-11.

3.

Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.

Lagas JS, van der Kruijssen CM, van de Wetering K, Beijnen JH, Schinkel AH.

Drug Metab Dispos. 2009 Jan;37(1):129-36. doi: 10.1124/dmd.108.023200. Epub 2008 Oct 9.

4.

Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.

Ge S, Yin T, Xu B, Gao S, Hu M.

Pharm Res. 2016 Mar;33(3):590-602. doi: 10.1007/s11095-015-1812-1. Epub 2015 Oct 26.

5.

"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.

Invest New Drugs. 2014 Dec;32(6):1083-95. doi: 10.1007/s10637-014-0143-0. Epub 2014 Jul 31.

PMID:
25078948
6.

Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.

Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, Schinkel AH.

Clin Cancer Res. 2009 May 1;15(9):3084-93. doi: 10.1158/1078-0432.CCR-08-2940. Epub 2009 Apr 21.

7.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3307-13.

8.

Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.

Roy U, Chakravarty G, Honer Zu Bentrup K, Mondal D.

Biol Pharm Bull. 2009 Dec;32(12):2002-9.

9.

Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.

Cholkar K, Trinh HM, Vadlapudi AD, Wang Z, Pal D, Mitra AK.

J Ocul Pharmacol Ther. 2015 May;31(4):248-55. doi: 10.1089/jop.2014.0144. Epub 2015 Apr 6.

10.

P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.

Chen C, Hanson E, Watson JW, Lee JS.

Drug Metab Dispos. 2003 Mar;31(3):312-8.

11.

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH.

Mol Cancer Ther. 2008 Aug;7(8):2280-7. doi: 10.1158/1535-7163.MCT-07-2250.

12.

Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K, Löscher W.

Br J Pharmacol. 2010 Jul;160(6):1453-63. doi: 10.1111/j.1476-5381.2010.00801.x.

14.

Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.

Fahrmayr C, König J, Auge D, Mieth M, Fromm MF.

Br J Pharmacol. 2012 Mar;165(6):1836-1847. doi: 10.1111/j.1476-5381.2011.01672.x.

15.

Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.

Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL.

Antimicrob Agents Chemother. 2007 Sep;51(9):3230-4. Epub 2007 Jun 18.

16.

Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.

Wortelboer HM, Usta M, van der Velde AE, Boersma MG, Spenkelink B, van Zanden JJ, Rietjens IM, van Bladeren PJ, Cnubben NH.

Chem Res Toxicol. 2003 Dec;16(12):1642-51.

PMID:
14680379
17.
18.

Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.

Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK.

Int J Pharm. 2010 Aug 16;395(1-2):114-21. doi: 10.1016/j.ijpharm.2010.05.027. Epub 2010 May 24.

19.

Multidrug resistance-associated protein 2 is involved in the efflux of Aconitum alkaloids determined by MRP2-MDCKII cells.

Dai P, Zhu L, Yang X, Zhao M, Shi J, Wang Y, Lu L, Liu Z.

Life Sci. 2015 Apr 15;127:66-72. doi: 10.1016/j.lfs.2015.02.011. Epub 2015 Mar 2.

PMID:
25744397
20.

Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.

Sampson KE, Brinker A, Pratt J, Venkatraman N, Xiao Y, Blasberg J, Steiner T, Bourner M, Thompson DC.

Drug Metab Dispos. 2015 Feb;43(2):199-207. doi: 10.1124/dmd.114.057216. Epub 2014 Nov 11.

Supplemental Content

Support Center